<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199341</url>
  </required_header>
  <id_info>
    <org_study_id>D9830C00017</org_study_id>
    <secondary_id>2010-021956-24</secondary_id>
    <nct_id>NCT01199341</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin</brief_title>
  <official_title>A Phase I, Open Label, Randomised, Parallel Group Study of Repeated Oral Doses of AZD1981 (100 mg Twice Daily and 400 mg Twice Daily) for Two Weeks and Single Doses of Warfarin (25 mg) to Evaluate the Pharmacokinetic Interaction of AZD1981 and Warfarin and the Effect of AZD1981 on Warfarin Pharmacodynamics in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether the treatment with AZD1981 affect
      the exposure of Warfarin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics for (R)- and (S)-Warfarin, respectively measured by Cmax and Area Under the Curve (AUC)</measure>
    <time_frame>PK sampling will be performed regularly from Day 1 to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore possible changes in the anticoagulative activity of Warfarin measured by INR .</measure>
    <time_frame>Will be performed at screening and at all visits during the study period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics for AZD1981 measured by AUCτ, Css,max, tmax,ss and CLss/F</measure>
    <time_frame>PK sampling will be performed regularly from Day 15 to Day 22.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD1981</measure>
    <time_frame>Safety will be monitored continuously and safety assessments will be made on several occasions throughout the whole study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pharmakokinetic</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981, low dose, + Warfarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981, high dose, + Warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>100 mg per oral, twice daily for 14 days</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>10 x 2.5 mg per oral, once daily at day 1 and day 15</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Waran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>4 x 100 mg per oral, twice daily for 14 days</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a body mass index between 19 and 30 kg/m2 and weight at least 65 kg and no more
             than 100 kg

          -  Be a non-smoker or ex-smoker who has stopped smoking for &gt;6 months prior to screening

          -  Volunteers must be willing to use barrier methods of contraception during study and 3
             months after the end of their participation in the study

        Exclusion Criteria:

          -  Volunteer that is inferred to have an increased sensitivity to warfarin based on
             genotype of CYP2C9 and VKORC1.

          -  Any clinically significant disease or disorder

          -  Any clinically relevant abnormal findings in physical examination
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christer Hultqvist, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aslak Rautio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wofgang Kühn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>February 8, 2011</last_update_submitted>
  <last_update_submitted_qc>February 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Drug-Drug interaction</keyword>
  <keyword>warfarin</keyword>
  <keyword>AZD1981</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

